Title: Latent hazard in PC and BPH patients referred to antiandrogens:PC aggressiveness and NE differentiation
Abstract:Antiandrogen treatment of BPH often involves finasteride therapy yielding intraprostatic DHT deficiency. We reported that prolonged antiandrogen therapy may provoke the acquisition of neuroendocrine (...Antiandrogen treatment of BPH often involves finasteride therapy yielding intraprostatic DHT deficiency. We reported that prolonged antiandrogen therapy may provoke the acquisition of neuroendocrine (NE) activity within the prostate. NE differentiation is a risk factor for the development of an aggressive prostate cancer. This study was undertaken to elucidate the cancer development hazard in BPH patients (pts) treated with finasteride.Read More
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot